logo
Urgent recall for popular cereal that may contain pieces of METAL

Urgent recall for popular cereal that may contain pieces of METAL

Daily Mail​6 hours ago

Thousands of boxes of cereal have been recalled over fears that pieces of metal in the food could cause painful health problems for anyone who eats them.
Breakfast foods giant Post issued the recall on May 28 for their Honey Bunches of Oats cereal, which the US Food and Drug Administration has now declared as a 'Class II' recall alert.
That means the recalled product could lead to 'temporary or medically reversible adverse health consequences.'
In terms of ingesting metal, the damage can vary from mild to severe, with victims cracking and chipping teeth or potentially suffering pain and punctures in their stomach or intestines.
The recall specifically impacts over 5,300 boxes of Post's Honey Bunches of Oats with Almonds, sold in 48-ounce boxes with two bags inside.
The cereal was shipped to Sam's Club stores in California and Colorado and had a UPC code of 8 84912-01428 3.
Shoppers should check to see if their cereal has the 'Best If Used By' Dates APR0926 RCA or APR1026 RCA printed on the box.
If anyone has these boxes of Honey Bunches of Oats, the FDA and Post are urging customers to throw them out or return them to the same store for a refund or replacement.
Despite the warning, Post insists that none of the contaminated cereals 'reached store shelves.'
Still, the FDA designated the metal contamination a Class II recall on June 12 out of an abundance of caution.
This means the threat to public safety is only one level lower than the most severe recall, a Class I, meaning that the affected product could cause serious harm or even death.
Post and the FDA did not specify what kind of metal pieces were found in the 5,376 boxes of Honey Bunches of Oats, leaving it unclear if metal shavings, large fragments, or sharpened shards made their way into the cereal.
Consuming metal may also cause other painful injuries, including cuts to the mouth, tongue, or throat.
There is also a potential choking hazard, especially if the metal fragments are larger and the cereal is eaten by a child.
The FDA has not received any reports of any injuries tied to this recall. The boxes of Honey Bunches of Oats with Almonds from Sam's Club are the only Post cereal affected by this recall at the moment.
Post Consumer Brands also makes popular cereals like Raisin Bran, Bran Flakes, Golden Crisp, Grape-Nuts, Honeycombs, Alpha-Bits, PEBBLES, and Malt-O-Meal.
When it comes to their breakfast foods, a recall from Post is a very rare occurrence.
In fact, only Malt-O-Meal has been involved in any major health recalls over the last two decades.
The wide variety of puffed rice cereals were recalled by the FDA in 1998, 2008, and 2009. Each time, inspectors found the cereals had been contaminated with salmonella.
However, it's important to note that all three recalls came before Post officially acquired the Malt-O-Meal Company in 2015.
The last major food recall involving breakfast cereals came in 2024 when Quaker Oats was forced to pull 43 different granola products due to salmonella contamination.
Honey Bunches of Oats was first launched by Post Cereals in 1989. Vernon Herzing, a Post employee, is credited with creating the popular cereal while he was at home mixing various Post cereals into a unique blend.
His daughter, Kimberly, assisted in taste-testing various combinations at home, helping to refine the recipe.
After three years of development, the cereal was named with input from Post brand manager Eva Page, who suggested 'Honey Bunches of Oats' to reflect its combination of granola, oat, and honey.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Common pregnancy complication linked to childhood seizures
Common pregnancy complication linked to childhood seizures

The Independent

time34 minutes ago

  • The Independent

Common pregnancy complication linked to childhood seizures

A new study by University of Iowa Health Care researchers has found that gestational hypertension, which affects about 16 per cent of US pregnancies, is associated with an increased risk of seizures in children. The study, published in the Journal of Clinical Investigation, utilized clinical databases containing over 246 million patients and lab mice studies. Researchers found that children born to mothers with high blood pressure during pregnancy had significantly higher rates of seizures. Mice testing confirmed increased seizure sensitivity and death due to seizures in offspring exposed to gestational hypertension in the womb. The study also indicated that male offspring were more vulnerable and that brain inflammation played a significant role in the disease process, suggesting it may also do so in human children.

Second patient death reported with gene therapy for muscular dystrophy
Second patient death reported with gene therapy for muscular dystrophy

The Independent

time44 minutes ago

  • The Independent

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. 'Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients,' said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Dismissed members of CDC vaccine committee call Kennedy's actions 'destabilizing'
Dismissed members of CDC vaccine committee call Kennedy's actions 'destabilizing'

The Independent

timean hour ago

  • The Independent

Dismissed members of CDC vaccine committee call Kennedy's actions 'destabilizing'

All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions" made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread. Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings. Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation. 'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Association. The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. The removal of Wharton and CDC immunization staff cuts will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about what vaccines to recommend and not recommend to the public, the experts said. 'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote. A spokeswoman for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee. Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store